Roche has unveiled promising Phase Ib/IIa trial results suggesting its “brain shuttle” Alzheimer’s disease candidate trontinemab could be safer and more effective than approved therapies, and will begin a Phase III study later this year.
Roche needed to be convinced that trontinemab could do better than the disappointing profiles of approved beta-amyloid targeting antibodies, Biogen/Eisai’s...
Welcome to Scrip
Create an account to read this article
Already a subscriber?